Anika Therapeutics
ANIK
130 hedge funds and large institutions have $179M invested in Anika Therapeutics in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 18 closing their positions.
9,133% more call options, than puts
Call options by funds: $277K | Put options by funds: $3K
52% more capital invested
Capital invested by funds: $117M → $179M (+$61.6M)
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
7.45% more ownership
Funds ownership: 84.77% → 92.22% (+7.5%)
3% more funds holding
Funds holding: 126 → 130 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.16M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.36M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.21M |
| 4 |
Morgan Stanley
New York
|
+$1.16M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
-$1.62M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.17M |
| 3 |
Jane Street
New York
|
-$933K |
| 4 |
D.E. Shaw & Co
New York
|
-$791K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$734K |
ANIK Hedge Fund Activity: Q1 2026 in Review
130 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2026, worth a combined $179M — up 52% from $117M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ANIK positions and 18 closed out — a net gain of 6 holders — while 50 added to existing stakes and 40 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $3.16M. The largest seller was Trigran Investments, exiting entirely with an estimated $1.62M sold.
- 130 institutional investors held Anika Therapeutics (ANIK) as of Q1 2026, up from 126 in Q4 2025.
- Funds reported $179M of Anika Therapeutics stock for Q1 2026, up 52% quarter-over-quarter.
- 24 funds opened new Anika Therapeutics positions in Q1 2026 and 18 closed out, a net change of +6 holders.
- The largest Anika Therapeutics buyer in Q1 2026 was Deutsche Bank, an estimated $3.16M added.
- The largest Anika Therapeutics seller in Q1 2026 was Trigran Investments, an estimated $1.62M sold.
Based on aggregated 13F filings for Q1 2026.